Research Article
Hyperuricemic PRP in Tendon Cells
Table 2
Relative gene expression normalised to the mean of GAPDH and TBP () given as medians and 25–75 percentiles.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Relative expression levels of tendon cells from three donors (T1, T2, and T3) treated with allogeneic PRP (six donors) for 96 hours, normalised to the mean of GAPDH and TBP () given as medians and 25–75 percentiles. Scleraxis (SCX), decorin (DCN), tenomodulin (TNMD), cartilage oligomeric protein (COMP), aggrecan (ACAN), SRY (sex determining region Y)-box 9 (SOX9), collagen type I alpha 1 (COL1A1), collagen type 3 alpha 1 (COL3A1), collagen type II alpha 1 (COL2A1), hyaluronan synthase 2 (HAS2), interleukin-1, beta (IL-1b), interleukin-6 (IL-6), interleukin-8 (IL-8), cytochrome c oxidase 1 (COX1), cytochrome c oxidase 2 (COX2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and TATA box binding protein (TBP). |